Clinical Research Directory
Browse clinical research sites, groups, and studies.
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
Sponsor: Ain Shams University
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation of the joints, leading to pain, swelling, disability, and reduced quality of life. Current therapies, although effective, may have limited efficacy or tolerability in some patients. Biological DMARDs are often associated with adverse effects, including increased risk of serious infections and heart failure. Long-term use may also increase the risk of malignancies. These limitations, together with their high cost. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has shown potential anti-inflammatory properties in addition to its antidepressant effects. This study aims to evaluate the efficacy and safety of venlafaxine as an adjunct therapy in the management of rheumatoid arthritis.
Official title: The Effect of Venlafaxine as an Adjunct Therapy on The Clinical Outcome of Rheumatoid Arthritis Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-03-26
Completion Date
2026-12-26
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
venlafaxine extended-release (XR)
35 patients will receive the standard RA treatment in addition to venlafaxine extended-release (XR) initiated at a dose of 75 mg/day for one week to ensure tolerability, followed by an increase to 150 mg/day, which will be maintained for the duration of the study (12 weeks)
Standard conventional Rheumatoid Arthritis Therapy
35 patients will receive the standard treatment of RA, which will be maintained for the duration of the study (12 weeks).